You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
News on CRISPR, gene editing, RNAi in genetics, genomics, and molecular diagnostics.
The Broad Institute's CRISPR paralog screening platform will inform Ideaya's synthetic lethality-based target and biomarker discoveries.
The company's approach combines whole-genome sequencing, CRISPR, liquid biopsy, and gene therapy to target cancer cells with gene fusions.
Christiana Care researchers have identified a unique protospacer adjacent motif site that allows them to knock out the NRF2 gene in tumor cells while leaving normal cells alone.
The Canadian company said its technology platform allows it to match patients to cancer treatments more efficiently and to identify novel patient populations.
Researchers used a genome-scale CRISPRi platform to identify genetic interactions with an inhibitor for a mutant form of KRAS in models of lung and pancreatic cancer.
In this session, the third in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review patient cases in which genomic profiling has identified gene fusions that may or may not serve as druggable targets.